
Opinion|Videos|January 16, 2025
Navigating Between Front-line Systemic Therapies in uHCC.
Author(s)James J. Harding, MD
James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Consider the other 1L systemic therapies in uHCC. How do the responses with NIVO + IPI therapy in CheckMate 9DW compare with other 1L IO regimens? HIMALAYA 5-year update (STRIDE),
Rimassa et al, ESMO 2024 and IMbrave150 (ATEZO + BEV),Cheng et al, J Hepatol 2022 .
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































